#Sweden #Stockholm #Capital Markets Day #S Swedish Orphan Biovitrum

Save the Date: Capital Markets Day at Sobi

Swedish Orphan Biovitrum AB, commonly known as Sobi, has announced an exciting opportunity for investors, analysts, and stakeholders with its upcoming Capital Markets Day (CMD). This much-anticipated event is scheduled for February 18, 2026, at 1:00 PM CET, taking place in person in Stockholm, Sweden. For those unable to attend in person, a live webcast will be available, ensuring that remote participants can also engage with the presentations.

This CMD promises to be a thorough exploration of Sobi’s strategic objectives and a platform to discuss the company’s advancements in therapy areas driven by healthcare professionals. Attendees can look forward to informative presentations led by Sobi's CEO, Guido Oelkers, along with key management team members. These sessions will not only include discussions on Sobi's growth strategies but will also feature interactive Q&A segments, allowing for direct dialogue between participants and executives.

The event is expected to wrap up around 4:00 PM CET, leaving ample time for participants to delve into the information being shared and to engage with company representatives. Stakeholders will glean valuable insights into how Sobi plans to navigate the future landscape of biopharma, especially as the company is committed to unlocking innovative treatments for individuals with rare diseases.

Early registration for the event is encouraged to ensure a spot. Stakeholders interested in attending can find pre-registration details available online. Stay tuned for a comprehensive invitation that will outline the full agenda and provide further details as the event approaches.

Founded in 2001, Sobi has established itself as a significant player in the biopharmaceutical arena, focusing on bringing transformative therapies to market for patients suffering from rare diseases. With a team of approximately 1,900 employees across various global regions including Europe, North America, the Middle East, Asia, and Australia, Sobi is well-positioned to leverage its expertise and resources to make a difference in the lives of patients. Their revenue reached SEK 26 billion in 2024, underscoring the successful trajectory the company is on and the high regard in which it is held in the biopharma community.

The company's shares trade on Nasdaq Stockholm under the symbol STO SOBI, reflecting its strong performance and robust market presence. More information about Sobi and their initiatives can also be found on their official website and LinkedIn page.

With the Capital Markets Day on the horizon, this event is an excellent opportunity for all interested parties to gain an understanding of where Sobi is headed and to engage directly with the leaders shaping its future. Make sure to mark your calendar for February 18, 2026, and participate in an event that stands to provide crucial insights into the evolving world of biopharma.